Preview Newsletter
XARELTO Media Monitoring – Week of 6-3-16
-
Investigation of Defective Device Used In Clinical Trials Occurs As Xarelto Lawsuit Filings Increase
May 30, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the mounting controversy over a 3-year long Xarelto clinical testing conducted by Duke University researchers for the manufacturers of the blood-thinning drug, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG. The clinical trial is now under investigation and the results of the trial are being questioned due to the use of a recalled blood testing device. It is also being alleged that the manufacturers purposefully kept quiet after noticing the omission of the data related to the device. Because of this silence, incomplete drug information was sent to US and European regulators and also to the New England Journal of Medicine (NEJM), whose assessment of Xarelto based on this faulty testing data most likely led to FDA approval of the drug. -
Blood Thinner Alternatives Available As Xarelto Lawsuit Plaintiffs Await Investigation Results
May 31, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on alternative blood clot therapies such as that offered by Vascular PRN as per an article in SBWire. Vascular PRN provides patients who are at an increased risk of blood clots a prevention method that does not carry with it dangerous risks such as those associated with Xarelto and other blood-thinning drugs. The company distributes pneumatic compression devices that utilize alternating compression to improve blood flow and prevent clotting in patients in nursing homes that are immobile or those recovering from major surgery. -
Alternative Treatments Available As Xarelto Lawsuit Filings Increase
May 31, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the controversy swirling about Xarelto, a blood-thinning drug developed by Janssen Pharmaceuticals, a Johnson and Johnson division, and Bayer AG, and approved by the U.S. Food and Drug Administration (FDA) in 2011. There have been in excess of 3,000 lawsuits filed, with 2,800 federal cases being consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) under the jurisdiction of a federal court judge in the Eastern District of Louisiana. Additionally, 600 more lawsuits were consolidated by the Court of Common Pleas in Philadelphia, PA. Expectations are that the number of cases will increase even further. -
Xarelto Lawsuit Filings Continue As Alternative Blood Clot Prevention Is Made Available
May 31, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on Xarelto and the ongoing controversy surrounding the drug. When Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011, it was a widely popular blood-thinning treatment. The blood thinner drug is now, however, the focus of investigations that are looking into its initial approval stages and whether integral data obtained during clinical trials was omitted when information was sent to reputable medical journals. -
Xarelto Lawsuit Consolidation Occurs Forming MDL 2592
Jun 1, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on Xarelto bleeding lawsuits that have been filed in many federal courts across the country under the jurisdiction of Hon. U.S. District Judge Eldon E. Fallon. The over 2,800 cases have also been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) as of December 2015 since all of the cases encompass very similar allegations. This consolidation facilitates quicker litigation since discovery issues and conflicting rulings by multiple pre-trial judges is avoided and greatly lessens litigation costs and time expended by those persons involved in each case. -
Xarelto Lawsuit Plaintiffs Request Consolidation Of Cases
Jun 2, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on a hearing convened by the U.S. Judicial Panel for Multidistrict Litigation (JPML) addressing a request by a group of plaintiffs dated October 2015. The plaintiffs all allege that they or loved ones used Xarelto and had suffered from dangerous uncontrollable bleeding while taking the blood thinner. The group requested to have the over 2,800 similar cases to be litigated as a group since all were filed against the same defendants and possessed very similar allegations. -
Xarelto Lawsuit Consolidation Assigned To Judge Eldon E. Fallon
Jun 2, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on Xarelto lawsuits filed by plaintiffs who used the blood-thinning drug and experienced instances of uncontrolled dangerous bleeding. The lawsuits have been filed against Bayer AG and the subsidiary company of corporate giant Johnson & Johnson, Janssen Pharmaceuticals. Additionally, due to the cases being filed, numbering in excess of 2,800, and all against the same defendants with very similar allegations, a group of Xarelto patients petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) to have the cases consolidated and centralized. The consolidation hearing was heard on December 4, 2015. -
Xarelto Lawsuit Plaintiffs Note Defective Device Used In Clinical Trials Of Drug
Jun 3, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on a 3-year long clinical trial that the makers of Xarelto hired Duke University to undertake for Xarelto, a then newly developed blood-thinning drug. Xarelto trials began in 2006 and reviewed the blood-thinning effects in a sample of 14,000 patients of a Xarelto compared to warfarin, a more traditional blood thinner. There is currently an investigation underway about this particular clinical trial. Many are questioning the use of a defective testing device during the trials that would have influenced the results that ultimately indicated that Xarelto was more effective since the defective device in question allegedly gave patients the wrong dosage of warfarin. -
Xarelto Lawsuit Plaintiff Alleges Drug Caused Stroke
Jun 3, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on a lawsuit filed by an Ohio couple requesting over $150,000 to compensate them for pain and suffering related to the alleged adverse side effects of taking Xarelto, a blood-thinning drug approved by the U.S. Food and Drug Administration in 2011. The wife of the plaintiff couple was given Xarelto to treat her atrial fibrillation. After taking Xarelto for two months, she very suddenly experienced a gastrointestinal bleed, and anemia, as well as other injuries not specifically identified. The woman claims to still be impacted by the side effects of the drug that require long-term maintenance and monitoring. The monetary payment being sought is to cover both current and future medical bills related to her condition. -
New Xarelto Injury Lawsuit Filed
May 28, 2016 | Law Offices of Jeffrey S. Glassman
A man from Florida has filed a new Xarelto injury lawsuit against Janssen Pharmaceuticals (a division of Johnson & Johnson, which is the U.S. marketing partner of Xarelto) and Bayer A.G. which is the German pharmaceutical giant that manufactures the medication. As part of this lawsuit, he is claiming negligent manufacture of a defective drug, among several other related claims. -
Xarelto Side Effects – More than just uncontrolled bleeding
May 30, 2016 | Xarelto Lawsuit Information
By Meds News LLC
Xarelto (rivaroxaban) side effects include several types of uncontrolled bleeding which may pose a serious threat of injury and even death. Patients under treatment with this drug must be warned about the significant risks of adverse reactions such as bleedings, blood clots, haematomas, internal haemorrhages, and even death. The U.S. Food and Drug administration even issued the “Black Box”, the most threatening warning on this medication’s label, to inform patients about its risks. Our guide will list all the most dangerous complications as well as the minor ones. -
Why are people hiring Xarelto lawsuit lawyers?
May 30, 2016 | Cannonliruns
It has been seen that people from all across the world are seeking legal help against the manufacturers of the drug, Xarelto. Xarelto is basically a blood thinning drug. This drug has caused many people to suffer from some severe internal bleeding and other complications. -
Investigations Conducted On Xarelto Clinical Trials As Lawsuit Filings Continue
Jun 1, 2016 | Legal Examiner
By Laurence Banville
TheProductLawyers.com reports on AllGov.org’s discussion of the controversy related to the clinical trials for Xarelto conducted by the Duke Institute for Clinical Research in 2006. The website stated that the researchers had used blood testing devices in the clinical trials that were the focus of two U.S. Food and Drug Administration (FDA) warnings prior to the start of the research, as well as the subject of a recall notice after the trial was completed. -
Group of Plaintiffs Jointly File Xarelto Side Effects Lawsuit
Jun 1, 2016 | Top Class Actions
By Ashley Milano
A group of nine plaintiffs from several different states have come together to jointly file a lawsuit against the blood-thinning drug Xarelto. The plaintiffs claim Xarelto side effects cause them serious injuries or the death of family member. -
Florida Man Files Xarelto Side Effects Lawsuit
Jun 3, 2016 | Righting Injustice
By Jennifer Walker-Journey
Gregory Dunn, of Miami, Fla., is the latest person to file a lawsuit against the makers of Xarelto claiming the blood thinner caused him life threatening internal bleeding.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Investigation of Defective Device Used In Clinical Trials Occurs As Xarelto Lawsuit Filings Increase
May 30, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the mounting controversy over a 3-year long Xarelto clinical testing conducted by Duke University researchers for the manufacturers of the blood-thinning drug, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG. The clinical trial is now under investigation and the results of the trial are being questioned due to the use of a recalled blood testing device. It is also being alleged that the manufacturers purposefully kept quiet after noticing the omission of the data related to the device. Because of this silence, incomplete drug information was sent to US and European regulators and also to the New England Journal of Medicine (NEJM), whose assessment of Xarelto based on this faulty testing data most likely led to FDA approval of the drug.
As per a Business Insider article, Xarelto is now the focus of more than 5000 lawsuits with 500 claims of patients dying from using the drug. Plaintiffs and lawyers representing them wonder if the omitted data would have helped to prevent such a large number of lawsuits and unnecessary deaths allegedly resulting from use of the blood thinner drug.
The Duke University clinical trial involved the review of 14,000 patients and the effects of the blood-thinning drug on them compared to Warfarin, a predecessor blood thinning drug. Many believe the faulty testing device led to the appearance that Xarelto was more effective because the device failed to give patients the right dosage of Warfarin.
While the controversy continues to build over this particular clinical test, plaintiffs who have filed lawsuits against the manufacturers of Xarelto await their day in court when the first bellwether trials are set to begin in the spring of 2017. It is also anticipated that more cases will be filed as these plaintiffs await trial.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.fox8live.com/story/32098166/investigation-of-defective-device-used-in-clinical-trials-occurs-as-xarelto-lawsuit-filings-increase
-
Blood Thinner Alternatives Available As Xarelto Lawsuit Plaintiffs Await Investigation Results
May 31, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on alternative blood clot therapies such as that offered by Vascular PRN as per an article in SBWire. Vascular PRN provides patients who are at an increased risk of blood clots a prevention method that does not carry with it dangerous risks such as those associated with Xarelto and other blood-thinning drugs. The company distributes pneumatic compression devices that utilize alternating compression to improve blood flow and prevent clotting in patients in nursing homes that are immobile or those recovering from major surgery.
Greg Grambor is the President of Vascular PRN and he recently commented on the possibility of devices such as those his company distributes becoming a viable alternative to blood-thinning drug therapies. He stated that "In cases where embolism prevention is the primary concern, pneumatic compression is a terrific alternative or supplemental therapy to warfarin and Xarelto."
When Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011 it was a very popular blood-thinning treatment. However, since then the drug and its manufacturers, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG, have become the focus of much controversy. It is now considered by many to be dangerous as it has alleged to have precipitated instances of excessive bleeding that were fatal in many cases. It is also at the center of investigations over clinical trials that appear to have used a faulty medical device that created erroneous data overstating Xarelto's effectiveness. This alleged erroneous data was also transmitted to prestigious and reputable medical journals for assessment.
Additionally, Xarelto has been the focus of over 3,000 lawsuits that have been consolidated into two primary groups. The first is a multidistrict litigation (MDL 2592) encompassing over 2,800 federal cases. The second is a mass tort program in Philadelphia, PA consolidated by the Court of Common Pleas.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
https://www.pressadvantage.com/story/10349-blood-thinner-alternatives-available-as-xarelto-lawsuit-plaintiffs-await-investigation-results
-
Alternative Treatments Available As Xarelto Lawsuit Filings Increase
May 31, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the controversy swirling about Xarelto, a blood-thinning drug developed by Janssen Pharmaceuticals, a Johnson and Johnson division, and Bayer AG, and approved by the U.S. Food and Drug Administration (FDA) in 2011. There have been in excess of 3,000 lawsuits filed, with 2,800 federal cases being consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) under the jurisdiction of a federal court judge in the Eastern District of Louisiana. Additionally, 600 more lawsuits were consolidated by the Court of Common Pleas in Philadelphia, PA. Expectations are that the number of cases will increase even further.
The lawsuits have come from all parts of the United States. Plaintiffs claim that the drug is dangerous in that it allegedly causes sudden and sometimes fatal uncontrollable bleeding and many feel that the manufacturers misled the public in its marketing campaign to promote the blood-thinning drug.
More disturbing news has emerged related to the clinical trials for the drug where investigations have begun that are questioning data that was possibly omitted related to a faulty blood testing device when clinical trial results were forwarded to highly respected medical journals.
In light of extensive legal action and the faulty clinical trial device and data that may have given Xarelto a better result than it should have gotten, some members of the public are looking to alternative therapies such as Vascular PRN distributes.
As per an article from SBWire, Greg Grambor, the President of Vascular PRN provides alternative therapies to traditional blood thinners such as Xarelto, with pneumatic compression devices, that offer protection from blood clots without dangerous risks characteristic to Xarelto and other anticoagulant drugs.
Grambor has recently stated that with cases of embolism pneumatic compression is a great prevention alternative, as it improves the flow of blood in the limbs of patients who are immobile due to surgical procedures or for those nursing home residents that cannot move around much.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.kltv.com/story/32108084/alternative-treatments-available-as-xarelto-lawsuit-filings-increase
-
Xarelto Lawsuit Filings Continue As Alternative Blood Clot Prevention Is Made Available
May 31, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on Xarelto and the ongoing controversy surrounding the drug. When Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011, it was a widely popular blood-thinning treatment. The blood thinner drug is now, however, the focus of investigations that are looking into its initial approval stages and whether integral data obtained during clinical trials was omitted when information was sent to reputable medical journals.
In addition to these latest allegations related to the clinical trials, Xarelto is also currently at the heart of over 3,000 lawsuits, with 2,800 of these being federally-filed lawsuits consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) to form MDL 2592 under the oversight of a Federal Judge in Eastern Louisiana. In Philadelphia, PA, the Court of Common Pleas has consolidated another 600 or more cases into a mass tort program. There is an expectation that the numbers of cases in both of these groups will increase in the future.
Plaintiffs in these cases are alleging that the manufacturers of the drug, Janssen Pharmaceuticals, a subsidiary company of the Johnson and Johnson Corporation, and Bayer AG, purposefully and intentionally misled the public about the drug in its public media campaign to promote its sale. The plaintiffs also claim that Xarelto is dangerous in that it can cause instances of severe and sometimes fatal uncontrollable bleeding.
Given the swirling controversy over Xarelto and other blood-thinning drugs, it is likely that many people will be looking to alternative therapies such as those promoted by Vascular PRN. Vascular PRN distributes a pneumatic compression device that uses alternating compression to improve blood flow and prevent clots in those patients recovering from surgery or those who are immobile such as nursing home patients. Vascular PRN offers a blood clot therapy without the risks such as those that exist with anticoagulants.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.wrcbtv.com/story/32108082/xarelto-lawsuit-filings-continue-as-alternative-blood-clot-prevention-is-made-available
-
Xarelto Lawsuit Consolidation Occurs Forming MDL 2592
Jun 1, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on Xarelto bleeding lawsuits that have been filed in many federal courts across the country under the jurisdiction of Hon. U.S. District Judge Eldon E. Fallon. The over 2,800 cases have also been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) as of December 2015 since all of the cases encompass very similar allegations. This consolidation facilitates quicker litigation since discovery issues and conflicting rulings by multiple pre-trial judges is avoided and greatly lessens litigation costs and time expended by those persons involved in each case.
After the hearing held on December 4, 2015, the Judicial Panel arrived at the conclusion that due to the considerable amount of cases coming forth about Xarelto, litigating the multitude of cases on an informal basis would not be a practical solution and would only serve to burden those litigating all of the cases separately. The panel also stated that Judge Eldon Fallon was very accustomed to the multi-district litigation and would be able to provide the leadership needed to properly direct the consolidation proceedings.
The consolidation was spearheaded by a group of plaintiffs in a request dated October 2015 that asked that the cases be overseen in the Southern District of Illinois. Defendants in the case such as Bayer AG and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson Corporation, resisted the move to Illinois since they are located in New Jersey.
With the formation of the MDL, it is likely that more complaints will be filed by Xarelto patients that have used the blood thinner claiming that they have suffered dangerously uncontrolled bleeding episodes. After the initial creation of MDL 2592, the number of cases included in the consolidated litigation process increased and are expected to grow as the cases in this MDL awaits trial.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.wave3.com/story/32119315/xarelto-lawsuit-consolidation-occurs-forming-mdl-2592
-
Xarelto Lawsuit Plaintiffs Request Consolidation Of Cases
Jun 2, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on a hearing convened by the U.S. Judicial Panel for Multidistrict Litigation (JPML) addressing a request by a group of plaintiffs dated October 2015. The plaintiffs all allege that they or loved ones used Xarelto and had suffered from dangerous uncontrollable bleeding while taking the blood thinner. The group requested to have the over 2,800 similar cases to be litigated as a group since all were filed against the same defendants and possessed very similar allegations.
In a decision dated December 12, 2015, the consolidation was granted by the panel and it appointed U.S. District Judge Eldon E. Fallon of the Eastern District of Louisiana to oversee the federally-filed cases. The panel stated that Judge Fallon was willing and able to preside over the Multidistrict Litigation (MDL) and had the experience necessary to monitor a multidistrict litigation process. It also concurred that given the number of cases involving the same defendants with similar claims against them, that such informal coordination of the multitude of pending cases was impractical.
Since the multidistrict consolidation was announced the number of cases has escalated and is expected to continue to increase while the cases involved in the initial MDL await trial. The consolidation process will facilitate a much more streamlined litigation process since it will allow for non-duplicative discovery processes and having to deal with numerous conflicting rulings by different judges across the country. The MDL will also lessen overall litigation costs and the time spent by the parties involved to prepare for each individual case.
Defendants in all of the consolidated cases include Bayer AG and the subsidiary of the Johnson and Johnson Corporation, Janssen Pharmaceuticals. Since the defendants are located in New Jersey, they were opposed to the consolidation of the cases in the Southern District of Illinois and asked that the cases be transferred to New Jersey.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.ktvn.com/story/32129279/xarelto-lawsuit-plaintiffs-request-consolidation-of-cases
-
Xarelto Lawsuit Consolidation Assigned To Judge Eldon E. Fallon
Jun 2, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on Xarelto lawsuits filed by plaintiffs who used the blood-thinning drug and experienced instances of uncontrolled dangerous bleeding. The lawsuits have been filed against Bayer AG and the subsidiary company of corporate giant Johnson & Johnson, Janssen Pharmaceuticals. Additionally, due to the cases being filed, numbering in excess of 2,800, and all against the same defendants with very similar allegations, a group of Xarelto patients petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) to have the cases consolidated and centralized. The consolidation hearing was heard on December 4, 2015.
The panel rendered a decision on December 12, 2015, and concurred with the petitioners that it was a prudent course of action to have the cases transferred and be litigated together. The panel stated that due to the immense growth of the number of cases being litigated, it demonstrated the impracticality of having them all considered individually given that they were all against the same defendants and were similar in scope in terms of the allegations being made about the drug. The panel felt that the decision to consolidate was an easy one in that it would facilitate a more streamlined process, prevent lengthy and duplicative discovery searches, and avoid the potential for many conflicting decisions by numerous judges in other jurisdictions. The legal expenses and time spent by all of the parties involved in each individual case would be greatly minimized as well.
The panel further stated that it was assigning the multidistrict litigation to U.S. District Judge Eldon E. Fallon who was well versed in, willing and able to preside over this particular multidistrict litigation (MDL 2592) in a very prudent and effective fashion.
The defendants in the case had argued that the cases should be transferred to New Jersey since that was where they were located. Instead, the panel opted to assign the case to the Southern District of Illinois.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.kiiitv.com/story/32129432/xarelto-lawsuit-consolidation-assigned-to-judge-eldon-e-fallon
-
Xarelto Lawsuit Plaintiffs Note Defective Device Used In Clinical Trials Of Drug
Jun 3, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on a 3-year long clinical trial that the makers of Xarelto hired Duke University to undertake for Xarelto, a then newly developed blood-thinning drug. Xarelto trials began in 2006 and reviewed the blood-thinning effects in a sample of 14,000 patients of a Xarelto compared to warfarin, a more traditional blood thinner. There is currently an investigation underway about this particular clinical trial. Many are questioning the use of a defective testing device during the trials that would have influenced the results that ultimately indicated that Xarelto was more effective since the defective device in question allegedly gave patients the wrong dosage of warfarin.
A recent Business Insider article has stated that Xarelto has become the focus of more than 5,000 lawsuits, as well as 500 allegations of fatalities. Plaintiffs in these cases and others now question whether the data would have made a difference in assessing the safety of the drug.
It is also being reported that Duke Researchers may have failed to provide all the requisite data of the trial for publishing in the New England Journal of Medicine (NEJM). As a result, the manufacturers, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG, are being accused of intentional deception by not giving the NEJM all the necessary data for its assessment, which most likely led to FDA approval of the drug and its subsequent release on the market.
Lawyers in a legal briefing recently filed allege that the makers of Xarelto did not say anything after noticing Duke’s omitted data related to a recalled blood testing device used in the trial, as well as remaining quiet as the information about the drug was sent to US and European regulators. By doing so, Janssen and Bayer in effect misled the NEJM and the many readers who rely on the journal’s information, as well at the patients who would eventually use the drug.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.khq.com/story/32095388/xarelto-lawsuit-plaintiffs-note-defective-device-used-in-clinical-trials-of-drug
-
Xarelto Lawsuit Plaintiff Alleges Drug Caused Stroke
Jun 3, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on a lawsuit filed by an Ohio couple requesting over $150,000 to compensate them for pain and suffering related to the alleged adverse side effects of taking Xarelto, a blood-thinning drug approved by the U.S. Food and Drug Administration in 2011. The wife of the plaintiff couple was given Xarelto to treat her atrial fibrillation. After taking Xarelto for two months, she very suddenly experienced a gastrointestinal bleed, and anemia, as well as other injuries not specifically identified. The woman claims to still be impacted by the side effects of the drug that require long-term maintenance and monitoring. The monetary payment being sought is to cover both current and future medical bills related to her condition.
This lawsuit, along with over 3,400 others all across the country, has been brought against the makers of the drug, Janssen Pharmaceuticals, a division of corporate giant Johnson and Johnson, and Bayer AG. The plaintiffs in this case, as well as the others, commonly allege that the use of the anticoagulant has made the risk of experiencing instances of excessive bleeding more likely. Some of the bleeding episodes have proven to be fatal. The plaintiffs also generally claim that the manufacturers of Xarelto failed to adequately and sufficiently inform the public and those medical professionals prescribing the drug of the dangers and risks involved in using it.
When Xarelto was initially approved by the FDA its intended use was for treating patients with medical conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The drug was also designed to treat patients that had undergone hip and knee replacement surgeries. The FDA has now issued two black box warnings for the blood thinning drug. Black box warnings are considered quite severe and a telling indication that a product could be on the verge of being wholly removed from the consumer market.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
http://www.digitaljournal.com/pr/2955553#ixzz4AXhGBTnO
-
New Xarelto Injury Lawsuit Filed
May 28, 2016 | Law Offices of Jeffrey S. Glassman
A man from Florida has filed a new Xarelto injury lawsuit against Janssen Pharmaceuticals (a division of Johnson & Johnson, which is the U.S. marketing partner of Xarelto) and Bayer A.G. which is the German pharmaceutical giant that manufactures the medication. As part of this lawsuit, he is claiming negligent manufacture of a defective drug, among several other related claims.
The lawsuit was filed in a United States District Court and technically has several more named defendants than listed above because each of these other companies have several wholly owned subsidiaries that were involved in the manufacture and marketing of Xarelto according to a recent news article from theLouisiana Record.
The complaint alleged that plaintiff used Xarelto for around a year beginning in the summer of 2013. He claims, while taking Xarelto, he started to experience internal bleeding in his gastrointestinal tract beginning in September of the following year. He was in severe pain and suffering and could have died from the internal bleeding condition. He further alleges that the painful condition is irreversible and has led to permanent damage.
As our Boston Xarelto injury lawyers have seen in far too many cases, this negligence is a result of the companies who designed, tested, and marketed the dangerous drug, choosing not to investigate likely safety concerns related to the need to adjust the dose.
Xarelto is designed primarily for patients who have a serious medical condition know as atrial fibrillation (Afib) or another serious medical condition know as deep vein thrombosis (DVT). Afib is defined as an irregular heartbeat not caused by defective heart valve, and DVT is a related condition whereby blood clots can form deep within the veins of the legs. These clots can then break free and travel through the victim’s circulatory system where they punch a hole in the lungs known as pulmonary embolism (PE) or block the flow of oxygenated blood to the brain, resulting in a stroke.
The traditional medication for many years was Warfarin (Coumadin), and, while this drug works, the dose has to be closely monitored through frequent blood tests and watching of a patient’s diet. If the dose is off, a serious bleeding condition can occur, but there is a reversal agent.
The makers of Xarelto marketed their drug as being much safer and having the same dose for all patients. Now in these many Xarelto injury lawsuits, plaintiffs are alleging there was a need to monitor and change the dose, and the company did not do needed tests and failed to disclose the seriously important information. There are also allegations that the company did not disclose this known potential danger to the United States Food and Drug Administration (FDA) in their application to put the drug on the market or in their required aftermarket follow up testing.
This particular plaintiff is asking for a trial by jury and is asking for various different types of damages. It should be noted that many of these cases will become consolidated as courts do not want to try the same issue or set of facts over and over again in the interest of judicial economy.
If you are the victim of Massachusetts product liability, call the Law Offices of Jeffrey S. Glassman for a free and confidential appointment — 1-888-367-2900.
http://www.productliabilitylawyerblog.com/2016/05/new-xarelto-injury-lawsuit-filed.html
-
Xarelto Side Effects – More than just uncontrolled bleeding
May 30, 2016 | Xarelto Lawsuit Information
By Meds News LLC
Xarelto (rivaroxaban) side effects include several types of uncontrolled bleeding which may pose a serious threat of injury and even death. Patients under treatment with this drug must be warned about the significant risks of adverse reactions such as bleedings, blood clots, haematomas, internal haemorrhages, and even death. The U.S. Food and Drug administration even issued the “Black Box”, the most threatening warning on this medication’s label, to inform patients about its risks. Our guide will list all the most dangerous complications as well as the minor ones.
Uncontrolled Bleedings
According to the medication’s monograph, the most common rivaroxaban side effects are the bleeding complications. However, several types of bleeding may threaten a patient’s health and, in some circumstances, even his or her life. Some external hemorrhages can, in fact, be obviously manifest like gum or hemorrhoidal bleedings, while some other hidden ones like the dreaded gastrointestinal bleeding and the internal hematomas can be much more subtle and dangerous indeed. Let’s give a look to all the different bleeding types to know more about them.
Brain Bleeding
One of the most dangerous types of Xarelto bleeding is the lethal brain bleeding (a type of stroke). Although only a single case study described a case of intracranial hemorrhage caused by the use of rivaroxaban, there is still a risk of brain bleeding associated with the use of this drug. Rivaroxaban full prescribing information does, in fact, include a risk of intracranial bleeding among the others described, albeit at a seemingly lower rate than with other Vitamin K inhibitors such as Warfarin. Just like any other anticoagulant, this medication is associated with several bleeding events. What makes this drug stand out from its competitors, however, is the fact that there’s no antidote available to reverse its effects once they’re set in. Just like any other uncontrolled bleeding event, a cerebral hemorrhage may require hours to subside, while doctors cannot do much else than just waiting for the drug to be flushed out from the patient’s body.
What is a Brain Bleeding?
An intracranial bleed is a type of stroke in which a brain vessel ruptures causing blood to leak into nearby tissues. The blood that is collected in the brain tissues irritates them, causing swelling (edema) as well as cellular death due to its toxicity. Blood and fluids start accumulating, forming a mass of clotted blood called hematoma which may exert a certain pressure on nearby regions which may reduce local perfusion. As the other regions receive less blood, the oxygen supply may become inadequate, causing more cells to die in a relatively short time span. Cerebral blood clots formed may even migrate to other regions of the brain or the body or the body. If a blood pouch bursts out on or near the brain surface, it may fill the space between the skull and the brain, causing a subarachnoid hemorrhage or a subdural hematoma.
How does a brain bleed occur?
If a part of the brain loses its blood supply for too much time, it may stop working, causing an ischemic stroke. Consequences of a stroke may vary, depending on the size and severity of the areas involved, and may range from simpler symptoms such as impaired vision or speech, weakness on one side, loss of balance or coordination, confusion, or even sudden seizures and coma. Sometimes symptoms of brain hemorrhage may progress slowly over the course of many days, while other times they may be abrupt and worsen in a matter of minutes. Strokes may be very insidious and dangerous, as they cannot be seen from the outside, and can only be confirmed by a CT scan. Some of the symptoms that are most frequently associated with this condition include:
Unusual and/or severe headaches
Confusion
Lack of balance and coordination
Nausea or Vomiting
Impaired Vision or Hearing
Loss of consciousness
Numbness
Weakness on one side of the body
Difficulty speaking or understanding speech
Seizures
Coma
Gastrointestinal Bleeding
Gastrointestinal bleeding (GI bleeding) is one of the most common forms of hidden bleeding caused by this dangerous blood thinner. Several studies pointed out how GI bleeding is more frequent in patients treated with rivaroxaban than those treated with Warfarin. Gastrointestinal bleeding rates in patients treated with rivaroxaban were, in fact, 42% higher than Warfarin GI hemorrhage rates, and tend to be more frequent and severe among older patients aged 75 years or over. GI bleeding risk is higher when patients are prescribed other anticoagulants such as antiplatelet agents or nonsteroidal anti-inflammatory drugs (NSAIDs).
This form of hemorrhage can be so small that only lab tests can detect it, but still be threatening because of the long-term effects of blood loss. Gastrointestinal bleedings can happen in any tract of the digestive tract including the esophagus, stomach, small intestine, colon, rectum, and anus. Hemorrhoidal bleedings (piles) are included in this category, as lower digestive tract hemorrhages. Piles can ben painful or painless, depending whether they become swollen and inflamed or not. Constipation and increased abdominal pressure can be the cause of hemorrhoids, and always represent detrimental factors to their development. This type of bleeding in patients under treatment with this drug can be more concerning than usual, and frequently require additional examination to be fully evaluated. Profuse bleeding from the hemorrhoids which can’t be stopped may require emergency treatment.
Symptoms of gastrointestinal hemorrhage include:
Bright red blood in vomit
Vomit that looks like coffee grounds
Black or tarry stool, or covered with bright red blood
Pain and irritation around the anal area
Unusual headaches
Constant fatigue and/or dizziness
Pale skin
External Bleeding
External bleeding include all kind of bleedings caused by cuts and perforations. Even holding a knife can be dangerous while under treatment with this anticoagulant medication, as the lack of an antidote prevents doctors from stopping the bleeding. Immediate application of a firm, direct pressure on the wound can help staunch the bleeding. However, due to the anticoagulant action of the medication, you may need to press for a longer time than usual before the bleeding stops. If blood does not stop pouring out after a while, you should check immediate help. Even minor bleeding accidents such as a nosebleed or a gum bleeding provoked by toothbrushing should never be underestimated. Try to avoid forceful nose blowing, and buy a toothbrush with soft bristles to reduce the chance of a gum bleeding. The most common forms of external bleeding include:
Gum Bleeding
Nose Bleeding
Skin Bleeding
Menstrual Bleeding
For women taking rivaroxaban, experiencing longer or heavier menstruations is a common side effect. However, uncontrolled menstrual bleeding can also represent a risk that should be addressed immediately. If you experience a bleeding during your menstrual cycle that is heavier than normal, you should call your doctor or seek medical help as soon as possible. Vaginal bleeding can also be caused by external traumas or during normal sex intercourse. You may also be interested in knowing about contraception while taking rivaroxaban.
Other Hidden Bleedings
The hidden bleedings include all kind of small injuries and trauma which can lead to internal hemorrhages. Even a simple accident like a fall can be very dangerous while under treatment with Xarelto. Basic safety precautions are of paramount importance for any patient who wishes to avoid ending in an emergency room, and even small bruises should never be underestimated. Internal bleeding caused by trauma can be very severe, and the lack of a proper reversal agent further endangers a patient’s health whenever this kind of accidents do happen. Other forms of hidden bleeding can also happen under the skin or scalp, manifesting themselves as small blisters or unusual skin folding. Patients under treatment with this medication should always be wary of sports injuries and other forms of internal bleeding including:
Bruises
Falling
Blunt trauma
Joint pain
Back Pain
Legs or abdominal pain
Unusually dry skin
Blisters or Skin folding
Blood in the urines
Sudden stop and increased risk of blood clots
Although this drug is used to prevent blood clots from forming (thrombosis), an increased risk of thromboembolic events can be the consequence of treatment discontinuation. If a patient suddenly stops treatment with rivaroxaban, there is a substantial risk of a blood clot forming inside his vessels. A blood clot traveling to the brain or lungs can cause major damage such as an embolism, and its complications may lead to paralysis or even be lethal. Due to the “once daily” dosage, there’s no way to reduce or adjust the actual dose taken by a patient. Whenever a new contraindication during therapy comes out, there’s no proper way to taper down the dosage slowly. In the event of a sudden mandatory stop in treatment, such as in the occasion of a bleeding accident, the patient’s health may be significantly endangered.
How dangerous is to stop taking Xarelto?
Temporary interruptions of therapy are quite frequent during anticoagulation therapy, especially in patients who suffer from in atrial fibrillation (one of the main indications of this drug). However, discontinuation of treatment with oral blood thinners is linked with a substantial risk of stroke, blood clots, and bleeding accidents. Patients should never stop taking this drug without informing their doctor, and they should be closely monitored to avoid the risk of further complications.
A study published in the Journal of the American College of Cardiology showed that Xarelto increases the risk of blood clots formation by the same amount Warfarin does, proving that the newer drug is not safer than the old one. The risk of blood clots and thromboembolic events may rise by up to 3 times during the first three months after treatment is suspended, then gradually falls during the next six months.
Wound infections and surgical complications
Wound leakage, infections, and increased return-to-surgery rates are all consequences of the use of this drug in hospitalized patients. One of the indications of this medication is the prophylaxis of deep vein thrombosis (DVT) after orthopedic surgery, such as hip or knee replacement. However, some recent researches published in the Journal of Bone & Joint Surgery suggested that this drug may be linked to an increased risk of complications. Since the drug dosage cannot be adequately adjusted to the patient’s need, its anticoagulation properties are often excessively effective, leading to ruptures, wound oozing and drainage, and the formation of blood pools called hematomas. A prolonged drainage may require longer hospitalization as well as the risk of chronic pain and further adverse reactions that may lead to reintervention. The study also showed that many patients had to return to the operating room to receive additional surgery due to an increased rate of wound infections. There are many other alternatives available to physicians to prevent blood clots after orthopedic surgery, ranging from aspirin and low-molecular-weight heparins, to non-pharmacological solutions such as physical rehabilitation and compression stockings.
Spontaneous Spinal Hematoma
One of the most dangerous complications during treatment with this medication is the risk of spontaneous spinal epidural hematoma in patients undergoing spinal puncture or receiving neuraxial anesthesia. The drug’s label includes a special Black Box warning to alert patients about this terrible adverse reaction. Epidural and spinal hematomas occurred in patients treated with this medication may result in permanent or long-term paralysis. Doctors must consider this risk before scheduling a patient to general anesthesia or spinal procedures. It should also be noted how the risk for this type of blood pooling is further increased by just a contemporary treatment with common NSAIDs.
What is a Spontaneous Spinal Epidural Hematoma (SSEH)?
Spontaneous spinal epidural hematoma (SSEH) is a somewhat uncommon spinal condition that may severely threaten a patient’s health. It is a large pool of blood leaked from spinal vessels (hematoma) that exerts pressure on nearby tissues. It usually presents itself as sudden neck or back pain that will eventually cause a general paresis of the limbs. The spontaneous development of spinal epidural hematomas is usually associated with the use of blood thinners such as this one. However, while other anticoagulants therapy can be suspended before the surgical procedure, sudden discontinuation of this drug may endanger a patient’s health. On the other hand, once a patient is affected by spinal hematoma, there’s not much that doctors could do to save his life or prevent paralysis. The management strategies to treat this condition are still unknown, as no evidence-based guidelines are available, forcing physicians to treat this dangerous adverse reaction empirically.
Minor side effects
Even lesser issues need to be mentioned, as a patient’s quality of life is an important factor that needs to be taken into consideration for long-term treatments. Subjects who take this drug need to take it for several months, if not for their entire life. Minor problems such as hair loss or dry skin can be very detrimental to his or her quality of life on the long run. Minor adverse reactions include:
Hair loss
Dry skin
Back and joint pain
Diarrhea
Leg cramps
Weakness and fatigue
Dizziness
Fever and chills
Headaches
Bladder dysfunctions
https://xareltolawsuits.net/xarelto-side-effects-more-than-just-uncontrolled-bleeding/
-
Why are people hiring Xarelto lawsuit lawyers?
May 30, 2016 | Cannonliruns
It has been seen that people from all across the world are seeking legal help against the manufacturers of the drug, Xarelto. Xarelto is basically a blood thinning drug. This drug has caused many people to suffer from some severe internal bleeding and other complications. Hence people have been hiring Xarelto lawsuit lawyers and are filing a case against the manufactures of the drug. People, who are seeking legal help, are basically those people who have suffered from severe injuries caused by the drug. These injuries include Intracranial Hemorrhage, Spinal and Epidural Hematoma, Gastrointestinal Hemorrhage, Adrenal Bleeding, strokes and blood clots as well. Anyone who has suffered from extreme complications and injuries, due to this drug, now has the right to file a case against the manufacturers. People have a chance to purse a case against them and so they are being provided by legal guidance to determine whether they can file a case or not.
No solution to the injuries caused!
Xarelto was introduced to the market by Bayer and Johnson & Johnson as better alternative to warfarin. Xarelto is used to prevent various injuries such as blood clots in people who suffer from atrial fibrillation. It is also being used to treat different kinds of blood clots such as deep vein thrombosis and pulmonary embolism. Xarelto is used for reducing any chances of developing a blood clot especially for those people who have undergone a joint replacement surgery. However it seems that the claims of Xarelto’s superiority might just not be true at all. There isn’t any solution for stopping internal bleeding caused by Xarelto. With warfarin you know that the bleeding can be stopped by taking vitamin K. but with Xarelto there is no solution, which makes this drug extremely dangerous to use.
People have been filing cases against the drug’s manufactures:
Throughout times, there have been many complaints which have been filed against the use of this drug. A number of Xarelto lawsuit lawyers have been hired by people who have suffered from uncontrollable bleeding caused by the medicine. These complaints are filed against manufacturers contain claims seeking compensation for all the medical bills and damages that have been caused due to the injuries. It is said that the manufacturers should have warned the people about the risks and complications they might face. The complaints also accuse them for portraying the drug to be a better option whereas they should have mentioned about the life threatening complications that one would have to face. And so, all those who have been injured by the usage of this drug can file a lawsuit. One can file out forms online and can even visit the offices as well. There are attorneys available who will guide you throughout the whole process, and will help you in filing a complaint.
http://www.cannoliruns.com/people-hiring-xarelto-lawsuit-lawyers/
-
Investigations Conducted On Xarelto Clinical Trials As Lawsuit Filings Continue
Jun 1, 2016 | Legal Examiner
By Laurence Banville
TheProductLawyers.com reports on AllGov.org’s discussion of the controversy related to the clinical trials for Xarelto conducted by the Duke Institute for Clinical Research in 2006. The website stated that the researchers had used blood testing devices in the clinical trials that were the focus of two U.S. Food and Drug Administration (FDA) warnings prior to the start of the research, as well as the subject of a recall notice after the trial was completed.
Potentially Life-Threatening Results
The Project on Government Oversight (POGO) weighed in on this issue as well stating that the faulty devices could have had the potential of registering false test results and that the use of the devices could have caused life-threatening effects and even death. The European Medical Association (EMA) is currently investigating the clinical trial and the use of the defective devices too.
Reservations Over Drug Approval
It should be noted too that the New York Times ran an article about the clinical trials. The Times article discusses the report by POGO, which noted that an FDA official overseeing the approval of Xarelto in 2011 expressed some reservations over the approval. The reviewers assigned to study the drug’s safety and effectiveness under the supervision of the FDA official noted that patients could be at a higher risk for stroke and uncontrollable bleeding with Xarelto than if they underwent treatment with warfarin, a blood thinner that has been available to consumers since the 1950’s.
Lawsuits Consolidated Into MDL
As these investigations progress, lawsuits against the drug and its manufacturers, Janssen Pharmaceuticals, a Johnson and Johnson subsidiary, and Bayer AG, continue to wind their way through the legal system. There are currently over 3,300 lawsuits pending and all plaintiffs are alleging that the blood-thinning drug induced in them sudden and very dangerous internal bleeding which resulted in the death of some patients. Many family members of the deceased patients have filed suit on their behalf as well.
http://newyorkcity.legalexaminer.com/fda-prescription-drugs/investigations-conducted-on-xarelto-clinical-trials-as-lawsuit-filings-continue/
-
Group of Plaintiffs Jointly File Xarelto Side Effects Lawsuit
Jun 1, 2016 | Top Class Actions
By Ashley Milano
A group of nine plaintiffs from several different states have come together to jointly file a lawsuit against the blood-thinning drug Xarelto.
The plaintiffs claim Xarelto side effects cause them serious injuries or the death of family member.
Xarelto Dangers and Risks
Xarelto was approved in July 2011 for the treatment and prevention of blood clots in patients going through hip and knee replacement surgery and for the prevention of stroke in patients with atrial fibrillation and for the prevention of deep vein thrombosis.
Xarelto is the first of a new generation of anticoagulant medications that have been advertised as being superior to warfarin, a drug that has been in use for 60 years.
People taking warfarin must have regular blood monitoring and the drug carries dietary restrictions; Xarelto does not. But there is no known antidote for Xarelto complications such as internal bleeding, while there is an antidote for warfarin.
The lack of an antidote is a serious concern: when a patient taking Xarelto experiences excessive bleeding, the person simply has to wait for the drug to clears from the system, which can make a bleeding episode dangerous and possibly even deadly.
Reported adverse Xarelto side effects Include
Brain hemorrhage
Gastrointestinal bleedingUncontrollable Internal Bleeding
These Xarelto complications can result in emergency hospital visits, extended hospital care for ongoing treatments, and in extreme cases, death.
Xarelto Side Effects Caused Injury, Death
Plaintiff Annie Edwards of Alabama, claims she ingested Xarelto for less than one month before she suffered severe bleeding for which she was hospitalized in April 2015.
Another plaintiff, Donnie P., who is being represented by his surviving wife Marion, died from alleged Xarelto complications in July 2014. He was prescribed Xarelto in March 2014.
The other named plaintiffs in the Xarelto lawsuit all assert similar claims that Xarelto side effects caused them to suffer life-threatening internal bleeding which required emergency medical intervention.
The charges in this Xarelto lawsuit include wrongful death, strict product liability, negligent misrepresentation, and fraud.
The plaintiffs are seeking compensatory, economic, punitive, and exemplary damages for Janssen’s alleged disregard and reckless indifference for the safety and welfare of the general public by failing to warn of dangerous Xarelto side effects.
Xarelto Litigation
Meanwhile, Xarelto lawsuits have been piling up, with plaintiffs claiming injuries and even death from the drug.
These cases form two major groupings: more than 2,800 federal lawsuits have been consolidated into a multidistrict litigation (MDL) Eastern Louisiana, while another 620 cases form a mass tort program in the Court of Common Pleas in Philadelphia, Pennsylvania.
According to these lawsuits, without a Xarelto antidote, doctors have no effective means of stopping a patients from bleeding in the event of an emergency.
The lawsuits also claim that patients and doctors should have been better warned about Xarelto side effects and risks and are now seeking compensation from the drug maker for medical bills, funeral expenses and other losses.
The Xarelto Lawsuit is filed within the larger consolidated multidistrict litigation In Re: Xarelto Products Liability Litigation, MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/336605-group-plaintiffs-jointly-file-xarelto-side-effects-lawsuit/
-
Florida Man Files Xarelto Side Effects Lawsuit
Jun 3, 2016 | Righting Injustice
By Jennifer Walker-Journey
Gregory Dunn, of Miami, Fla., is the latest person to file a lawsuit against the makers ofXarelto claiming the blood thinner caused him life threatening internal bleeding.
Dunn filed his lawsuit in the U.S. District Court for the Eastern District of Louisianaagainst Johnson & Johnson, Janssen Pharmaceuticals, Bayer, and their related companies alleging they violated the Consumer Protection Law and failed to adequately warn doctors and patients aboutXarelto side effects.
Dunn claims he started using Xarelto on July 23, 2013, and continued to use it through Aug. 29, 2014. On Sept. 5, 2014, he suffered gastrointestinal bleeding, a condition he links to his Xarelto use and says is life threatening and irreversible, and caused him severe pain and suffering.
Xarelto was approved in 2011 and is currently approved to prevent strokes in patients with atrial fibrillation, to treat and prevent deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients who have recently undergone hip or knee replacement surgery.
Dunn’s lawsuit is one of hundreds that have been filed against Johnson & Johnson’s Janssen and Bayer over Xarelto side effects. Plaintiffs claim that the drug makers did not adequately test Xarelto to fully understand its risks. Xarelto has been linked to serious bleeding risks including gastrointestinal bleeds, rectal bleeds, brain hemorrhages and bleeding deaths. There is also no antidote to reverse the blood thinning effects of Xarelto in the event of a bleeding emergency.
http://www.rightinginjustice.com/news/2016/05/31/florida-man-files-xarelto-side-effects-lawsuit/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested